ALK Positive

We are a patient-driven organization, dedicated to improving the life expectancy & quality of life for ALK-positive cancer patients worldwide. #StrongerTogether

[ALK Positive @ALKPositiveinc]

#ASCO2026 reinforced what’s possible when patients are part of the process. We connected with researchers, industry partners, and advocates, discussed emerging ALK+ cancer data, and helped shape future studies. We leave with new ideas, new partnerships, and renewed determination.

[ALK Positive @ALKPositiveinc]

🚀 June is ALK-positive Awareness Month and #FuelTheCure is LIVE.
$650,000 goal. $60,000 raised. Every gift matched right now.

We are not just funding research. We are fueling the future.

👉 https://t.co/4A1mGOODtu
#FuelTheCure #APAM26 #LookingToTheStars

[ALK Positive @ALKPositiveinc]

We were thrilled to be live at #ASCO26 to hear Dr @vincentlamMD presenting the results of the ARCHER trial - a prophylactic peptide vaccine targeting ALK.

Thanks @oncodaily for sharing. More research = more hope & life

[OncoDaily @oncodaily]

@christine_lovly @vincentlamMD @HopkinsMedicine @ALKPositiveinc We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/1iWhQT0IUk

[OncoDaily @oncodaily]

@christine_lovly @vincentlamMD @HopkinsMedicine @ALKPositiveinc We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/1iWhQT0IUk

[Christine Lovly, MD, PhD, FASCO @christine_lovly]

#ASCO26 is amazing, but cost + time prohibitive for most patients. Look forward to a virtual chat with the powerhouse @ALKPositiveinc patient community to share updates + answer questions live from @ASCO! 5/31 6pm CST by Zoom ⬇️
#LCSM @alk_fusion @LUNGevity @YoungLungCancer

[ALK Positive @ALKPositiveinc]

Live from ASCO: ALKtALK with Dr. Christine Lovly

Get real-time updates from the ASCO Annual Meeting and what they mean for the ALK+ community—straight from a leading researcher and advocate.

📅 May 31, 2026
🕖 7 PM ET
📍 Zoom (broadcast live from ASCO)

[ALK Positive @ALKPositiveinc]

The 7-year CROWN data is in from #ASCO26. 💥

Key lorlatinib findings include long-term PFS, brain protection, and the importance of biomarker testing.

Join us live Sunday, May 31 at 7pm ET as Dr. Christine Lovly discusses the results and other #ASCO26 updates. 💙

[Yvonne Diaz @Yvonne_Diaz_]

Great to be here at #ASCO26 flying the flags for @OncogeneCancer and @ALKPositiveinc.

[Hidehito HORINOUCHI @HHorinouchi]

🆙 #ASCO26 #LCSM Oral
🔥CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC
✅mPFS NR (HR 0.19)
✅7-yr PFS 55% vs 3%
✅44% still on lorlatinib at 7y
✅No new IC progression after 30m
🎙️ @TonyMok9
🔢8502
☑️NCT03052608
🔗 https://t.co/vb2DOfxPsp
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc

[Urs Weber MD @UrsWeberMD]

@ALKPositiveinc Thank you for amplifying my post! It’s a really important message for oncologists as well. I see far too many of my colleagues pushing for 100mg no matter what it’s doing to the patient.

[Urs Weber MD @UrsWeberMD]

As impressive as lorlatinib is in the treatment of ALK+ NSCLC, there’s still room for improvement. Neladalkib can still produce a fair number of responses, including in the brain, post-lorlatinib. Attention patients, this drug can be accessed via an EAP! @ALKPositiveinc #ASCO2026

[ALK Positive @ALKPositiveinc]

@UrsWeberMD This is a key message for our ALK patient community. Thank you

[Urs Weber MD @UrsWeberMD]

Dose-reduced lorlatinib (50mg or 75mg) works just as well as full-dose lorlatinib (100mg). Don’t be afraid to reduce the dose (or even start at a lower dose) if patients are struggling with or worried about toxicity! @ALKPositiveinc #ASCO2026

[Stephen V Liu, MD @StephenVLiu]

Dr. @TonyMok9 at #ASCO26 presents update on CROWN in ALK+ NSCLC. After 7y, median PFS with lorlatinib still not reached. Between years 5 and 7, only 4 progression events occurred. Unusual but fantastic to see such a tail with targeted therapy - this is truly raising the bar.

[Eric K. Singhi, MD @lungoncdoc]

7yr CROWN update of 1L lorlatinib

55% progression-free at 7 YEARS.
Median PFS STILL not reached.

In metastatic solid tumors, this is essentially unheard of. Let that sink in.

And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26

[ALK Positive @ALKPositiveinc]

Our ALK Positive crew is rapt as the ALK lung cancer presentations kick off on this opening day of #ASCO26. Thank you Dr @TonyMok9 for presenting the latest 7 year CROWN data.

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🔥🚨@OncoAlert Hot off the press.

Just published @Annals_Oncology in conjunction with presentation @ASCO #ASCO26

⭐️7-Year #Updates from the:

👑 #CROWN phase 3 trial of #1st line #Lorlatinib vs #Crizotinib in Advanced #ALK+ Non–Small Cell #LungCancer

❇️❇️IMPRESSIVE Results

✅Median #PFS NOT REACHED at 7 years for Lorlatinib

✅7-yr PFS: 55% vs 3 %

👇🏼
https://t.co/L5bQuvLK4J

[ALK Positive @ALKPositiveinc]

@DaisyAlkie @Sunonmyhip We are inspired by community members like you! See you at the ALK Summit in DC soon.

[ALK Positive @ALKPositiveinc]

🔬 ALK Positive is heading to #ASCO26 in Chicago! Excited to learn from the latest ALK-positive lung cancer research, connect with the oncology community, and continue advocating for patients and families. If you’re attending, we hope to see you there! 👋

#ALKPositive

[Lung Cancers Today @Lung_Cancers]

👑 Coming up at #ASCO26: @TonyMok9 will present the 7-year data from the CROWN trial at 2 p.m. Central Time during the metastatic NSCLC oral abstract session!

🫁 Don't miss it!

➡️ Stay tuned for our coverage: https://t.co/0ZzNtp5Gk1